CALR mutations and human myeloproliferative neoplasms. (360G-Wellcome-104710_Z_14_Z)

£2,000,004

Myeloproliferative neoplasms are pre-leukaemic diseases in which abnormal bone marrow stem cells produce too many mature blood cells. These disorders are associated with increased thrombosis and the development of overt leukaemia. We have recently shown that many myeloproliferative neoplasm patients develop a mutation in the CALR gene. However CALR has not previously been linked to any malignancy and the molecular consequences of these mutations are completely unclear. This award will allow us to study how such mutations perturb normal blood cell formation and give rise to a myeloproliferative neoplasm.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Region East of England
Award Date 2014-07-08T00:00:00+00:00
Internal ID 104710/Z/14/Z
Planned Dates: End Date 2022-01-31T00:00:00+00:00
Planned Dates: Start Date 2015-08-01T00:00:00+00:00
Amount Awarded 2000004
Financial Year 2013/14
Lead Applicant Prof Tony Richard Green
Grant Programme: Title Investigator Award in Science
Applicant Surname Green
Approval Committee Science Interview Panel
Recipient Org: Country United Kingdom
Recipient Org: City Cambridge
Has the grant transferred? No
Research conducted at multiple locations? No
Total amount including partnership funding 2000004